Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

AAK’s Interim report for the fourth quarter and year-end report 2019 – continued profit growth and new strategic direction

AAK Group, fourth quarter · Total volumes for the quarter amounted to 582,000 MT (574,000), organic growth of 1 percent (4). · Sales amounted to SEK 7,380 million (6,992), an increase of 6 percent. · Operating profit, including a positive currency translation impact of SEK 12 million, reached SEK 562 million (516), an improvement of 9 percent. Operating profit per kilo improved by 8 percent to SEK 0.97 (0.90). · Net result amounted to SEK 401 million (354), an improvement of 13 percent. · Earnings per share increased by 12 percent, to SEK 1.56 (1.39). · Cash

Mandatory Notification of Trade

Ousdal AS, a company wholly owned by Riulf Rustad, chairman of the board of Norwegian Energy Company ASA (“Noreco”), has on 29 January 2020 acquired options to buy up to 400,000 shares in Noreco with a strike price of NOK 315 for a consideration of NOK 11 per option, valid until 30 November 2021. In connection with this transaction, Ousdal AS has sold 66,000 shares at a price of NOK 224 per share. Following these transactions, Riulf Rustad, and companies controlled by him, will own 146,975 shares and 890,000 options to buy or subscribe for shares in Noreco, in total 1,036,975 shares and

Gene expression analysis method has been validated by a commercial laboratory

GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announced that the method  for gene expression analysis has been validated by a commercial laboratory, a request from regulatory authorities for use in clinical practice.Academic data from approximately 450 patients, all treated with 5-FU and leucovorin containing regimens, has demonstrated a difference in PFS with patients having a high expression of certain folate relevant genes versus those who have lower expression levels. “With the validated gene expression analysis method,

UPM Financial Statements Release 2019: UPM reports good performance and record cash flow – Uruguay investment drives significant future earnings growth

UPM-Kymmene Corporation      Financial Statements Release 2019          30 January 2020 at 9:40 EET UPM Financial Statements Release 2019:UPM reports good performance and record cash flow – Uruguay investment drives significant future earnings growth Q4 2019 highlights · Sales decreased by 10% to EUR 2,447 million (2,731 million in Q4 2018) due to lower pulp price and lower deliveries of graphic papers · Comparable EBIT decreased by 15% to EUR 343 million (404 million) · Record quarterly operating cash flow at EUR 592 million (384 million) · Net debt decreased to EUR -

Follicum's Phase II study with FOL-005 for treatment of Alopecia approved by the German Medicines Agency

Follicum AB ("Follicum" or "the Company") today announces that it has received approval from the German Medicines Agency (BfArM) and the German Ethics Committee to start a Phase IIa clinical study with a topical formulation of FOL-005 on patients with alopecia (hair loss). The trial will comprise about 200 patients who will be treated with FOL-005 or placebo daily for 4 months. The study is conducted in collaboration with the Charité Clinical Research Center for Hair and Skin Science ("CRC") in Berlin and proDERM, Hamburg, Germany.In two previous clinical studies, FOL-005 has been shown to

Update on 2cureX’s clinical trial in metastatic colorectal cancer: 75% of the scheduled patients have been treated in accordance with the IndiTreat test

2cureX AB (“2cureX”, NASDAQ: 2CUREX) is pleased to announce that 35 patients have been treated in accordance with the IndiTreat test in our colorectal cancer trial (ClinicalTrials.gov Identifier: NCT03251612). We are thus on track and expect that all the planned 45 patients are treated by Q3, 2020.The clinical trial was initiated by Vejle University Hospital, selected by “Dagens Medicin” as the best cancer hospital in Denmark for four consecutive year Lars Henrik Jensen, Chief Oncologist and Chairman of Interdisciplinary Oncology Committee of the Danish Medicines Council, is the

Over 200 patients now randomized in the Global Phase 3 AGENT Study

GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announced that over 200 patients of the planned 440 has been randomized in the global Phase 3 AGENT Study. The study has over 80 clinical sites in the U.S., Canada, Europe, Australia and Japan. The target of 330 patients randomized for the interim analysis is expected to be achieved in the second quarter of 2020.Over 200 patients are now randomized in the Phase 3 AGENT Study, a registration clinical trial of arfolitixorin in first-line metastatic colorectal cancer (mCRC) patients. The

Medivir has received notices of allowance in the EU and Japan for MIV-818 patent applications

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) reports that the MIV-818 patent portfolio has been reinforced by the issue of notices of allowance from the European Patent Office and the Japanese Patent Office for the MIV-818 composition-of-matter and liver cancer treatment claims. Corresponding notices of allowance or patent grants have already been issued in USA, Australia, Indonesia, Israel, Philippines, Russia, Singapore and South Africa. Applications are pending in a large number of other countries in Asia and around the world. The patents will be in force until August 2035.

Klaria Pharma presents new strategy, upcoming milestones and new website

Today, Klaria Pharma Holding AB (publ) (”Klaria”) announces that it has formulated and is now implementing a new strategy. Klaria will focus all research and development exclusively on programs where Klaria’s films have the potential to replace injections or nasal sprays, and where formulations constitute a major problem for patients, caregivers or payers. Since Klaria’s Alginate Film technology has significant advantages to both injections and nasal sprays, this strategy ensures that resources are focused on programs where the unmet medical needs are significant and where development of oral

Year End Report 2019

Press release, Stockholm, Sweden, 30 January 2020 TagMaster’s profitable growth continues – the best result to date Fourth quarter · Net sales increased during the fourth quarter by 89,6% to 83,5 MSEK (44,1) · Adjusted EBITDA amounted to 8,7 MSEK (0,9), corresponding to a margin of 10,4% (2,0) · EBITDA for the fourth quarter amounted to 4,3 MSEK (0,9), corresponding to a margin of 5,2% (2,0) · Net result after tax was -9,4 MSEK (-0,5) whereof amortizations of goodwill in accordance with the standard accounting principles (K3) applied by TagMaster amounted to -9,7 MSEK

Baccarat added to Evolution’s award-winning Lightning range

Evolution Gaming, leading provider of Live Casino solutions, has added to its award-winning Lightning range with the launch of an exclusive, all-new game, Lightning Baccarat.This new Lightning game, which again combines live play with high-payout RNG multipliers, is part of Evolution’s line-up of new releases for ICE 2020 and is an exciting new take on classic Baccarat. As in standard Live Baccarat, players try to predict whose hand, Player or Banker, will win by having the value closest to 9. Unlike traditional Baccarat, however, after betting time has expired a Lightning Round begins

Evolution selected by Groupe Partouche for launch in the Swiss market

Evolution Gaming, leading provider of Live Casino solutions, announced today that it has been selected by Groupe Partouche to deliver online Live Casino services to the regulated Swiss market.Partouche’s Evolution-powered Live Casino — scheduled for launch during the first half of 2020 — will allow the group’s customers in Switzerland to play a rich mix of online live games on smartphones, tablet and desktop. The live games from Evolution’s wide-ranging, award-winning portfolio will include live dealer Roulette, Baccarat, numerous live dealer Poker variants, as well as games such as

Wallenstam invests in co-living in Kallebäcks Terrasser

Wallenstam and Colive have signed an agreement on developing co-living housing, a so-called “co-living hub” in Kallebäcks Terrasser, one of Gothenburg’s largest urban development areas. The agreement relates to co-living apartments for 117 tenants, divided between a seven-floor building and a five-floor building with expected occupation during fall 2022. Kallebäcks Terrasser in the longer term will consist of 1,800 new homes and 1,200 office workspaces as well as schools, nursery schools, restaurants, cafés and local services.“We already have a project together with Colive in Haninge and we

Beijer Ref AB Q4-2019

Increased profits, acquisition and increased dividendFourth quarter Net sales increased by 4.3% in the fourth quarter compared to the same period last year and amounted to SEK 3,435 million (3,293). Organic growth amounted to 0.9% and the rest of the increase represents positive currency effects. The operating profit for the quarter amounted to SEK 256 million (229), an increase of 11.8% compared with the same period last year. The operating margin amounted to 7.4% (6.9%). Net profit totalled SEK 183 million (164). Profit per share amounted to SEK 1.42 (1.28). The company's cash

All patients enrolled for ChloraSolv01

RLS Global is pleased to announce that all patients are included in the study ChloraSolv 01, which has been performed on nine sites in Sweden. The inclusion criteria for the study are chronic wounds below the knee. The aim with the study is to obtain clinical data to regulatory extend the indication for use (diabetic foot ulcers) to all types of chronical wounds below the knee (venous leg ulcers, arterial/mix wounds etc.). ChloraSolv01 is a pilot study. The patients are treated with ChloraSolv for six weeks with six weeks follow up. We are measuring, among other things, the differences of

The Phase 1/2a study ISO-CC-005 is completed

GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announces that the recruitment and treatment of patients in the company's Phase 1/2a study with arfolitixorin has been completed. Totally 101 patients have been treated at 10 hospitals in the Nordic countries and Europe. The final analysis has started and study data is expected to be presented at ESMO 2020.Ulf Jungnelius, M.D., Chief Executive Officer of Isofol, comments: “ISO-CC-005 has fulfilled its purpose by determining the dose we have chosen for further development in our Global

Attendo's year-end report for 2019 to be published on 13 February - Invitation to teleconference

On 13 February, around 08:00 am (CET), Attendo will present its year-end report and fourth quarter results for 2019. Investors, analysts and journalists are hereby invited to participate in a teleconference at 10:00 am (CET) on the same date.The teleconference will be hosted by Attendo’s CEO Martin Tivéus and CFO Fredrik Lagercrantz. The presentation will be held in English. Date:             13 February 2020Time:             10:00 am (CET) To participate in the conference, please dial in on any number below at least ten minutes before the start of the call: SE:

Citycon’s Financial Statements 2019 to be published on Thursday, 6 February 2020 at approximately 9 am EET

CITYCON OYJ   Investor News   30 January 2020 at 09.00 hrsCitycon will publish its Financial Statements and Financial Statements Release for the 1 January – 31 December 2019 period as well as its Corporate Governance Statement on Thursday, 6 February 2020 at approximately 9 am EET. The report will be available on Citycon’s website after publication.Citycon's investor, analyst and press conference call and live audiocast will begin one hour later at 10 am EET. The audiocast can be participated by calling in and followed live at https://citycon.videosync.fi/2019-q4-results/register

Wärtsilä's Board of Directors decides on a new share-based incentive scheme

Wärtsilä Corporation, Stock exchange release, 30 January 2020 at 9:00 AM EETWärtsilä's Board of Directors decides on a new share-based incentive schemeWärtsilä’s long-term incentive scheme 2020-2022 comprises 8,788,000 incentive rights. The reward is paid in shares. The reward is based on the share price development during a three-year period, with a starting share price of EUR 11.01. The reward cannot exceed EUR 4.31 per incentive right and it takes into account 100% of dividends paid out during the performance period and reinvested in the Company’s shares. The scheme will be due for

Q4 Report 2019 – invitation to conference call and audiocast

On Friday February 14, at 4.00 p.m. CET, IRRAS will host a conference call and an online presentation of its Q4 2019 interim report (which will have been published earlier on the 14[th] at 08.00 a.m. CET). The presentation will be held in English. The dial-in numbers for the conference call are: Sweden: +46 8 56 64 27 03Rest of the world: +44 33 33 00 92 67 The presentation will be webcast and can be accessed from the following web address:https://tv.streamfabriken.com/irras-q4-2019 Speakers: President CEO Kleanthis G. Xanthopoulos, Ph.D., CCO Will Martin and CFO Sabina

SAS ANNUAL AND SUSTAINABILITY REPORT – FISCAL YEAR 2019

At a Board meeting of SAS AB, the November 2018-October 2019 Annual and Sustainability Report for the SAS Group and its parent company SAS AB was presented and approved.The Annual Report is now available on the internet, www.sasgroup.net under Investor Relations. The Board of Directors proposes to the 2020 AGM that no dividends be paid to holders of SAS AB’s common shares for fiscal year 2019. Apart from this, the  report does not contain any new substantial information which has not already been disclosed in SAS’s year-end report or via separate press releases. For further

Sivers IMA confirms four new design wins

Sivers IMA Holding AB (Nasdaq First North Growth Market: SIVE) today announces four new design wins with Tier 3 customers, based on design using the Sivers IMAs unique 57-71 GHz RFIC, TRX-BF01.From March to December last year Sivers IMA shipped more than thirty-five (35) evaluation kits (EVK) to customers addressing several different verticals and use cases. In the first quarter 2019 Sivers IMA had 9 design-wins in total, we are now at 16 design-wins, reaching a 20% conversion rate from EVK to design-win, after 10 months. In this early design-win development phase we estimate a limited

Neste to publish its 2019 results on 7 February 2020

Neste Corporation, Press Release, 30 January 2020 at 9 a.m. (EET) Neste will publish its fourth quarter and full year 2019 results on Friday, 7 February 2020 at approximately 9 a.m. (EET). The release will be available on the Neste website  immediately after publishing. A conference call in English for investors and analysts will be held on 7 February 2020, at 3 p.m. Finland / 1 p.m. London / 8 a.m. New York. The call-in numbers are as follows: Finland: +358 (0) 9 4245 0806, rest of Europe: +44 (0) 20 7192 8000, US: +1 631 510

Q4 incl. Full Year Report 2019

Strong fundamentals in place to fuel strategy for future growth Q4 2019 highlights · Total net revenues of SEK 238.1 million (227.1), up 4.8 percent · Zubsolv® US net revenues of SEK 190.5 million (166.7), up 14.3 percent in SEK and 7.5 percent in local currency · Net earnings of SEK 38.9 million (51.6), down 24.6 percent · EBITDA of SEK 85.8 million (42.8), up 100.5 percent. EBITDA ex Abstral® of SEK 39.6 million (-9.6). · US EBIT of SEK 98.2 million (62.0), up 58,4 percent · Cash flow from operating activities of SEK 60.2 million (71.7), building a cash balance of

There are no items matching the current filter
There are no more items matching the current filter
Back to top